Letter to the editor
Robert G Newman
Baron Edmond de Rothschild Chemical, Dependency Institute of Beth Israel Medical Center, New York, NY, USA
In response to "Privacy protection for patients with substance use problems", there is indeed a compelling reason to worry about loosening of the Federal confidentiality regulation, 42 CFR Part 2, which requires special protection for patient information maintained by addiction treatment facilities. This concern is not so much based on fear of misuse and/or unauthorized further disclosure by the recipient of such information.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]